Recent news for Vivos Therapeutics includes capital raising through warrant exercises and analyst buy recommendations, reflecting ongoing financing activities and market interest.

• Vivos Therapeutics announced the closing of exercise of warrants for $4.64 million gross proceeds in January 2026 [N5].
• Ascendiant Capital maintained a buy recommendation for Vivos Therapeutics in December 2025 [N6].
• HC Wainwright & Co. initiated coverage of Vivos Therapeutics with a buy recommendation in November 2025 [N7].

The company’s transition to a medical-provider focused model with acquisitions and management of sleep centers could enable broader patient access to Vivos treatments and higher revenue per case. The integration of diagnostics, treatment, and administrative services through DSOs and MSOs may improve operational efficiency and contribution margins. The proprietary Vivos Method, with FDA-cleared appliances and adjunctive therapies, offers a differentiated non-surgical treatment option for OSA with potential durable benefits. Recent in-network insurance status for SCN entities and ongoing expansion of provider teams support potential growth in treatment volumes. The company’s active pipeline of acquisition targets and strategic alliances could further expand its footprint and revenue base.

Vivos Therapeutics has a history of operating losses and negative cash flow, with limited liquidity and significant current liabilities as of December 31, 2025. The new medical-provider focused business model is at an early stage, with operational constraints including limited physical space, provider recruitment challenges, and insurance credentialing delays that restrict patient capacity. The company’s ability to increase revenues, achieve profitability, and raise additional capital on favorable terms is uncertain. Dependence on third-party insurance reimbursement and patient out-of-pocket payments introduces variability in revenue. Failure to successfully integrate acquisitions or execute the new business model could impair financial performance. Market competition and changing patient or provider preferences also pose risks.

Vivos Therapeutics’ competitive advantages stem from its proprietary suite of FDA-cleared oral appliances and the comprehensive Vivos Method, which offers a non-surgical, minimally invasive treatment option for OSA with limited treatment duration and potential durable effects. The company’s pivot to a medical-provider focused business model, involving acquisitions and management of sleep medical practices and establishment of DSOs and MSOs, provides vertically integrated control over diagnostics, treatment, and administrative services. This integration enables higher contribution margins and scalability compared to the legacy dentist-focused model. Additionally, Vivos’ multidisciplinary approach, including adjunctive therapies and a broad provider network, enhances treatment effectiveness and patient access. The company’s intellectual property, clinical education infrastructure, and strategic alliances further support its market position.

• Financial and Liquidity Risks: The company has a history of net losses and negative cash flow, with limited cash reserves and a low current ratio as of December 31, 2025. It may require additional capital to fund operations and growth, which could result in dilution or increased debt obligations.
• Operational Execution Risks: Constraints such as limited physical space, challenges in recruiting and training Vivos-trained dentists and medical providers, and delays in insurance credentialing limit the company’s ability to meet patient demand and scale operations effectively.
• Business Model Transition Risks: The pivot from a legacy dentist-focused model to a medical-provider focused model is at an early stage. The success of acquisitions, strategic alliances, and management service organizations is uncertain and may not generate anticipated revenue or profitability.
• Regulatory and Reimbursement Risks: The company’s revenue depends in part on third-party insurance reimbursement and patient financing availability. Changes in healthcare regulations, insurance coverage policies, or reimbursement rates could adversely affect revenue.
• Market and Competitive Risks: The market for OSA treatments is competitive, with alternatives such as CPAP and surgical options. Changes in patient or provider preferences away from The Vivos Method could reduce demand and revenue.

• Vivos Therapeutics, Inc. is a revenue stage medical technology and healthcare services company specializing in proprietary oral appliances and therapeutic treatments for maxillofacial and developmental abnormalities related to breathing and sleep disorders such as obstructive sleep apnea (OSA) and snoring in adults [S1].
• The company’s core treatment approach is The Vivos Method, which combines oral appliances with therapeutic protocols and is estimated to be effective in approximately 80% of compliant OSA cases within FDA cleared uses [S1].
• Vivos has treated approximately 75,000 patients worldwide with its products, including about 60,000 with its patented C.A.R.E. oral appliances and an additional 15,000 with other appliance lines [S1].
• Since 2024, Vivos has shifted its business model from primarily training independent dentists to a medical-provider focused model that includes acquiring and managing sleep medical practices and establishing Dental and Medical Service Organizations (DSOs and MSOs) branded as Sleep and Airway Medicine Centers (SAMC) [S1].
• The company’s new model involves strategic alliances, acquisitions, and management agreements with sleep centers and medical providers to deliver diagnostics and treatment services, including Vivos products and CPAP [S1].
• In June 2025, Vivos acquired The Sleep Center of Nevada (SCN), integrating its operations and generating diagnostic revenue of $4.8 million and treatment revenue of $2.0 million in 2025 [S1].
• Operational constraints at SCN include limited physical space, provider and staff recruitment and training, and insurance credentialing delays, with demand exceeding capacity at onboarded locations [S1].
• Vivos deploys Sleep Optimization (SO) teams consisting of nurse practitioners, dentists, dental assistants, administrative staff, and treatment navigators to support patient care at SAMC locations [S1].
• Initial SO teams at SCN have demonstrated potential to generate collections exceeding $500,000 per month with contribution margins above 50% [S1].
• The company is expanding its MSO/DSO management model to include joint ownership management services entities with sleep center owners, retaining supermajority control [S1].
• Vivos offers a portfolio of FDA 510(k) cleared oral appliances including the DNA, mRNA, mmRNA, Vida, and Versa devices targeting various severities of OSA and related conditions such as TMD and bruxism [S1].
• The Vivos Method may include adjunctive therapies such as myofunctional therapy, chiropractic/physical therapy, and laser treatments [S1].
• Vivos provides additional services including home sleep screenings (VivoScore), treatment navigation, billing intelligence services, and telemedicine-based myofunctional therapy (MyoSync) [S1].
• The company operates The Vivos Institute, a clinical education center for training healthcare providers in sleep and airway medicine, though it is currently underutilized and partially sub-leased [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents of $2.03 million, current assets of $4.38 million, current liabilities of $18.08 million, net loss of $21.17 million, and basic/diluted EPS of -$2.07 [S1].
• Liquidity ratios as of December 31, 2025: current ratio of 0.24 and cash ratio of 0.11, indicating limited short-term liquidity [S1].
• The company has a history of operating losses and negative cash flow, with accumulated deficit of approximately $125.4 million as of December 31, 2025 [S1].
• Vivos has raised capital through equity offerings, warrant exercises, and convertible notes, including a $4.64 million gross proceeds from warrant exercises in January 2026 [N5][S1].
• The company faces risks related to its ability to increase revenues, achieve profitability, and raise additional capital on favorable terms [S1].
• Vivos is actively pursuing additional acquisitions and strategic alliances with sleep centers and medical providers to expand its new business model [S1].
• The company’s new model aims to provide more patients access to Vivos treatments, increase referral rates, and generate higher revenue and profit per case compared to its legacy dentist-focused model [S1].
• Vivos has received in-network status with several commercial health insurance payers and Medicare for its SCN physician-owned professional entities as of March 2026 [S1].
• Recent news includes the announcement of closing of warrant exercises for $4.64 million gross proceeds in January 2026 [N5], and analyst buy recommendations from Ascendiant Capital and HC Wainwright & Co. in late 2025 [N6][N7].